

Datasheet for ABIN2813028

anti-F12 antibody (Light Chain) (AbBy Fluor® 594)



oo to rioddot page

| Overview | |
|----------------------|--|
| Quantity: | 100 μL |
| Target: | F12 |
| Binding Specificity: | Light Chain |
| Reactivity: | Human, Mouse, Rat |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This F12 antibody is conjugated to AbBy Fluor® 594 |
| Application: | Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)) |
| Product Details | |
| Immunogen: | KLH conjugated synthetic peptide derived from human Coagulation factor XIIa light chain |
| Isotype: | IgG |
| Cross-Reactivity: | Human, Mouse, Rat |
| Purification: | Purified by Protein A. |
| Target Details | |
| Target: | F12 |
| Alternative Name: | Factor XII (F12 Products) |
| Background: | Synonyms: Factor XII, Coagulation factor XIIa light chain, Factor XII, Coagulation factor XII, Factor XII light chain, F12, F12 deficiency, FA12_HUMAN, Factor XII deficiency, HAE3, HAEX, |

HAF, HAF deficiency, Hageman factor, Beta-factor XIIa part 2.

Background: This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged. [provided by RefSeq, Jul 2008].

Gene ID: 2161

Pathways: Complement System

Application Details

Application Notes: IF(IHC-P)(1:50-200)

Restrictions: For Research Use only

Handling

| Format: | Liquid |
|--------------------|--|
| Concentration: | 1 μg/μL |
| Buffer: | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. |
| Preservative: | Sodium azide |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Storage: | -20 °C |
| Storage Comment: | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Expiry Date: | 12 months |